We are currently upgrading our print fulfillment systems. Print book orders placed between Sept 22 and Oct 9 will be delayed. Delivery of these orders will start on Oct 10, with purchases being fulfilled in the order received. Buy the Print and get eBook immediately for FREE. Use Code BOGO. Or save up to 40% on all orders with code: DELTA. Exclusions apply. Click here for terms and conditions.
»
Obesity Management and Redux
 
 

Obesity Management and Redux, 1st Edition

 
Obesity Management and Redux, 1st Edition,Stylianos Nicolaidis,ISBN9780080537917
 
 
 

  

Academic Press

9780080537917

144

New Study on Revolutionary Anti-Obesity Drug!

eBook
eBook Overview

VST format:

DRM Free included formats: PDF

USD 32.95
Add to Cart
 
 

Key Features

@introbul:Key Features
@bul:* Covers all aspects of a revolutionary new drug
* Lists pharmacological profile of the drug
* Includes safety data
* Projects future trends in weight management

Description

Redux™ is a revolutionary new anti-obesity drug that has just been approved (July 1996) by the FDA. It is the first weight management drug treatment to be launched in the United States in 20 years and is not addictive, unlike earlier drugs used for this purpose. Obesity Management and Redux™ includes a brief introduction which leads up to its discovery and includes an overview of new trends in obesity management. The book lists the pharmacological profile of the drug, given by experts involved in monitoring the effects of the drug on the brain neurotransmitters, as well as detailing the results (including safety data) of the various clinical trials.

Readership

Scientists interested in normal and disordered eating and drinking.

Stylianos Nicolaidis

Affiliations and Expertise

CNRS Directeur, College de France

Obesity Management and Redux, 1st Edition

M. Derome-Tremblay, The Story of Dexfenfluramine and Its History over the Past 30 Years. S. Nicolaidis and R. Essner, Marketing in the United States: Labeling and Major Marketing Options. G. Bray, New Trends in the Management of Obesity in the U.S. Pharmacological Profile: R. Wurtman, Brain Neurotransmitters. S. Garattini, Neurochemical Mode of Action of Drugs Which Modify Feeding via 5HT System. J. Blundell, Effects on Eating Patternsand Motivation in Humans Methods for Assessing Neurochemical Changes and their Effect: M. Kalia, The Signifcance of DF Induced Neurochemical Changes, 1976&150#1995. J. OCallaghan, Glial Reaction as an Indicator of Neurotoxicity. R. Moore, The Long-Term DF Study. S. Lorens, DF Effects on Behaviour. B. Campbell, Pharmacokinetic Consideration in Assessing Neurochemical Changes. Therapeutic Efficacy: G. Cooper and R. Sandage, Overview of the Clinical Data. B.Guy-Grand, The INDEX Study: New Data. R. Noble, An 18-Month Study in Overweight American Patients. G. Faich, PPH/Key Discussion Points. N. Laudignon and M. Rebuffe-Scrive, Overview of the Safety Data. Round Table Discussion: V. Itallie, Benefit/Risk Ration of the Treatment of Obesity.
 
 
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ